INS and type 2 diabetes mellitus: Semaglutide demonstrated efficacy in glycemic control and body weight reduction compared to placebo and active comparators, such as sitagliptin, exenatide extended-release, dulaglutide, and insulin glargine, in the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) clinical trials [26,27,28,29,30].